Devansu Tewari is an Oncology physician affiliated with Kaiser Permanente. OpenAlex indexes 57 publications with 1,213 citations (h-index 14); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Comparing Strategies for Implementing Primary HPV Screening
Sponsor: Chun Chao
- Improving Tumor Oxygenation in Cervical Cancer
Sponsor: University of California, Irvine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
- INTUITIVE SURGICAL, INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
35.9%Estrogen Agonist/Antagonist15.9%Tamoxifen Citrate100%Part D<11 patientsPoly(ADP-Ribose) Polymerase Inhibitor12.4%Lynparza100%Part D<11 patients+ 1 more class in this area
Nervous system
16.6%Nonsteroidal Anti-inflammatory Drug16.6%Ibuprofen100%Part D≥23 patientsGenitourinary & hormones
13.8%Progestin13.8%Megestrol Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Factors accounting for excess uterine cancer mortality among insured Black versus White patients treated within the same US health care system
International Journal of Gynecological Cancer
2026 - Evaluating the trend of time to colposcopy follow-up among women with a positive primary human papillomavirus screening result at Kaiser Permanente Southern California
American Journal of Obstetrics and Gynecology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Louis Fehrenbacher, MD
Kaiser Permanente
Susy Peng, MD
Kaiser Permanente
Prasanth Manthena, MD
Kaiser Permanente
Alan Go, MD
Kaiser Permanente
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”